(MedPage Today) — At the American Society of Clinical Oncology (ASCO) meeting, phase II findings suggested that intratumoral dendritic cell therapy combined with HER2-targeted treatment may enhance immune activity and improve pathologic complete…
Source: MedPage Today — Headlines
